Brooks Laboratories Limited (BROOKS.BO)
INR 123.5
(9.05%)
INR 123.5
(9.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 41.72 Million INR | 110.76% |
| 2022 | -291.68 Million INR | -111.03% |
| 2021 | -134.5 Million INR | -1208.2% |
| 2020 | 12.52 Million INR | 153.08% |
| 2019 | -35.15 Million INR | 55.18% |
| 2018 | -54.85 Million INR | 38.11% |
| 2017 | -86.84 Million INR | -272.6% |
| 2016 | 50.41 Million INR | -60.28% |
| 2015 | 113.23 Million INR | 35.02% |
| 2014 | 68.61 Million INR | 10.53% |
| 2013 | 85.24 Million INR | -19.24% |
| 2012 | 104.71 Million INR | 0.26% |
| 2011 | 113.61 Million INR | 11.22% |
| 2010 | 93.19 Million INR | 27.58% |
| 2009 | 75.08 Million INR | 28.4% |
| 2008 | 57.54 Million INR | 5.43% |
| 2007 | 54.58 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.8 Million INR | -586.7% |
| 2023 Q1 | 245 Thousand INR | 100.6% |
| 2023 Q2 | -10.09 Million INR | -4218.78% |
| 2023 Q3 | -32.05 Million INR | -217.61% |
| 2023 Q4 | 3.8 Million INR | 111.87% |
| 2023 FY | - INR | 110.76% |
| 2022 Q1 | -85.65 Million INR | -97.77% |
| 2022 Q2 | -88.23 Million INR | -3.01% |
| 2022 Q3 | -84.58 Million INR | 4.14% |
| 2022 Q4 | -40.55 Million INR | 52.05% |
| 2022 FY | - INR | -111.03% |
| 2021 FY | - INR | -1208.2% |
| 2021 Q2 | -41.68 Million INR | -1010.15% |
| 2021 Q4 | -43.3 Million INR | 27.98% |
| 2021 Q3 | -60.13 Million INR | -44.25% |
| 2021 Q1 | 4.58 Million INR | 110.32% |
| 2020 FY | - INR | 153.08% |
| 2020 Q1 | -1.34 Million INR | -134.51% |
| 2020 Q2 | 58.76 Million INR | 4456.34% |
| 2020 Q3 | -560 Thousand INR | -100.95% |
| 2020 Q4 | -44.37 Million INR | -7823.75% |
| 2019 Q4 | 3.9 Million INR | 144.18% |
| 2019 Q2 | -18.58 Million INR | -3183.75% |
| 2019 Q3 | -8.84 Million INR | 52.4% |
| 2019 FY | - INR | 55.18% |
| 2019 Q1 | -566 Thousand INR | -140.23% |
| 2018 Q3 | -7.82 Million INR | 45.58% |
| 2018 FY | - INR | 38.11% |
| 2018 Q2 | -14.38 Million INR | 56.36% |
| 2018 Q1 | -32.95 Million INR | -103.31% |
| 2018 Q4 | 1.4 Million INR | 117.98% |
| 2017 Q3 | -9.76 Million INR | 63.01% |
| 2017 Q1 | -34.1 Million INR | -422.73% |
| 2017 FY | - INR | -272.6% |
| 2017 Q4 | -16.2 Million INR | -65.91% |
| 2017 Q2 | -26.41 Million INR | 22.56% |
| 2016 FY | - INR | -60.28% |
| 2016 Q4 | -6.52 Million INR | -152.01% |
| 2016 Q3 | 12.54 Million INR | -22.84% |
| 2016 Q1 | 29.37 Million INR | -25.95% |
| 2016 Q2 | 16.25 Million INR | -44.66% |
| 2015 FY | - INR | 35.02% |
| 2015 Q3 | 35.69 Million INR | 14.75% |
| 2015 Q2 | 31.1 Million INR | 55.6% |
| 2015 Q1 | 19.98 Million INR | -53.28% |
| 2015 Q4 | 39.66 Million INR | 11.14% |
| 2014 Q1 | 17.93 Million INR | -25.64% |
| 2014 Q4 | 42.78 Million INR | 55.68% |
| 2014 FY | - INR | 10.53% |
| 2014 Q2 | 598 Thousand INR | -96.67% |
| 2014 Q3 | 27.48 Million INR | 4495.65% |
| 2013 Q2 | 21.95 Million INR | -0.07% |
| 2013 Q4 | 24.12 Million INR | 41.5% |
| 2013 FY | - INR | -19.24% |
| 2013 Q3 | 17.04 Million INR | -22.36% |
| 2013 Q1 | 21.97 Million INR | 16.2% |
| 2012 Q3 | 32.5 Million INR | 3.83% |
| 2012 Q2 | 31.3 Million INR | 39.73% |
| 2012 Q4 | 18.9 Million INR | -41.82% |
| 2012 Q1 | 22.4 Million INR | -2.84% |
| 2012 FY | - INR | 0.26% |
| 2011 Q2 | 31 Million INR | 0.0% |
| 2011 Q4 | 23.05 Million INR | -28.84% |
| 2011 FY | - INR | 11.22% |
| 2011 Q3 | 32.4 Million INR | 4.52% |
| 2010 FY | - INR | 27.58% |
| 2009 FY | - INR | 28.4% |
| 2008 FY | - INR | 5.43% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 99.566% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.932% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 99.392% |
| Granules India Limited | 8.6 Billion INR | 99.515% |
| Indoco Remedies Limited | 2.64 Billion INR | 98.424% |
| Achyut Healthcare Limited | 524 Thousand INR | -7863.359% |
| Ajanta Pharma Limited | 12.56 Billion INR | 99.668% |
| Alkem Laboratories Limited | 24.19 Billion INR | 99.828% |
| Alpa Laboratories Limited | 86.12 Million INR | 51.551% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 98.229% |
| Bajaj HealthCare Limited | 444.51 Million INR | 90.613% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 97.179% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.953% |
| Eris Lifesciences Limited | 6.98 Billion INR | 99.403% |
| FDC Limited | 4.4 Billion INR | 99.052% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 99.632% |
| Gufic Biosciences Limited | 1.48 Billion INR | 97.181% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 99.392% |
| Ipca Laboratories Limited | 13.29 Billion INR | 99.686% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 87.099% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 150.441% |
| Lasa Supergenerics Limited | -65.08 Million INR | 164.118% |
| Laurus Labs Limited | 8 Billion INR | 99.479% |
| Lupin Limited | 36.96 Billion INR | 99.887% |
| Mankind Pharma Limited | 28.09 Billion INR | 99.851% |
| Medicamen Biotech Limited | 245.66 Million INR | 83.014% |
| Medico Remedies Limited | 150.37 Million INR | 72.251% |
| Megasoft Limited | 284.73 Million INR | 85.345% |
| NATCO Pharma Limited | 18.79 Billion INR | 99.778% |
| Piramal Pharma Limited | 13.05 Billion INR | 99.68% |
| RPG Life Sciences Limited | 1.28 Billion INR | 96.744% |
| Sigachi Industries Limited | 883.39 Million INR | 95.276% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.97% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 99.108% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 90.302% |
| Unichem Laboratories Limited | 742.35 Million INR | 94.379% |
| Wanbury Limited | 985.49 Million INR | 95.766% |
| Windlas Biotech Limited | 781.72 Million INR | 94.662% |
| ZIM Laboratories Limited | 462.09 Million INR | 90.97% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.926% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 101.118% |
| Divi's Laboratories Limited | 25.43 Billion INR | 99.836% |
| Hester Biosciences Limited | 539.47 Million INR | 92.265% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 98.616% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 93.886% |
| Bal Pharma Limited | 345.59 Million INR | 87.926% |
| Strides Pharma Science Limited | 3.76 Billion INR | 98.892% |
| Venus Remedies Limited | 711.8 Million INR | 94.138% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 98.933% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 97.332% |
| Shilpa Medicare Limited | 2.58 Billion INR | 98.388% |
| Aarti Drugs Limited | 3.24 Billion INR | 98.716% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 98.399% |
| Suven Life Sciences Limited | -992.78 Million INR | 104.203% |
| Ind-Swift Limited | 1.06 Billion INR | 96.082% |
| Valiant Laboratories Limited | 12.73 Million INR | -227.561% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 99.553% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 101.479% |
| Themis Medicare Limited | 562.6 Million INR | 92.583% |
| Hikal Limited | 2.69 Billion INR | 98.45% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.881% |
| Sequent Scientific Limited | 549.8 Million INR | 92.41% |
| Novartis India Limited | 1.26 Billion INR | 96.713% |
| Wockhardt Limited | 1.08 Billion INR | 96.136% |
| Jubilant Pharmova Limited | 8 Billion INR | 99.479% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -219.461% |
| Neuland Laboratories Limited | 4.74 Billion INR | 99.121% |
| Morepen Laboratories Limited | 1.72 Billion INR | 97.582% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 85.482% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 76.148% |